文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.

作者信息

Singal Amit G, Hoshida Yujin, Pinato David J, Marrero Jorge, Nault Jean-Charles, Paradis Valerie, Tayob Nabihah, Sherman Morris, Lim Young Suk, Feng Ziding, Lok Anna S, Rinaudo Jo Ann, Srivastava Sudhir, Llovet Josep M, Villanueva Augusto

机构信息

Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, Texas.

Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, Texas.

出版信息

Gastroenterology. 2021 Jun;160(7):2572-2584. doi: 10.1053/j.gastro.2021.01.233. Epub 2021 Mar 9.

DOI:10.1053/j.gastro.2021.01.233
PMID:33705745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8169638/
Abstract
摘要

相似文献

[1]
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.

Gastroenterology. 2021-6

[2]
A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis.

Cancer Prev Res (Phila). 2021-6

[3]
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.

Hepatology. 2022-3

[4]
Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma.

J Int Med Res. 2020-2

[5]
Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis.

Gastroenterology. 2025-3

[6]
Extracellular mRNA detected by molecular beacons in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma.

PLoS One. 2018-6-7

[7]
A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse.

PLoS One. 2013-7-10

[8]
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2018-10-1

[9]
Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis.

World J Gastroenterol. 2019-8-14

[10]
Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10.

Gut. 2013-11

引用本文的文献

[1]
A serum TNFR2-based model effectively predicates preoperative microvascular invasion and stratifies the tumor recurrence risk in hepatocellular carcinoma.

BMC Gastroenterol. 2025-8-27

[2]
Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.

Hepatology. 2025-9-1

[3]
The Search for Prognostic Biomarkers in Patients with Surgically Treated Hepatocellular Carcinoma.

J Clin Exp Hepatol. 2025

[4]
Pyroptosis drives tumor progression and immune evasion in Hepatocellular Carcinoma: a single-cell and spatial transcriptomic study.

Discov Oncol. 2025-5-20

[5]
Multicenter evaluation of abbreviated MRI and ultrasound for detecting early-stage hepatocellular carcinoma.

JHEP Rep. 2025-2-12

[6]
Superior Diagnostic Yield of Core Needle Biopsy Over Fine Needle Aspiration in Diagnosing Follicular-Patterned Neoplasms: A Multicenter Study Focusing on Bethesda IV Results.

Korean J Radiol. 2025-6

[7]
Des-γ-carboxy Prothrombin in hepatocellular carcinoma post-operative recurrence risk evaluation.

Commun Med (Lond). 2025-3-6

[8]
Persisting challenges in the early detection of hepatocellular carcinoma.

Expert Rev Anticancer Ther. 2025-2-24

[9]
Liver diseases: epidemiology, causes, trends and predictions.

Signal Transduct Target Ther. 2025-2-5

[10]
Development of a Novel four-gene Model for Monitoring the Progression from Metabolic Dysfunction-associated Steatotic Liver Disease to Hepatocellular Carcinoma in Males.

J Cancer. 2025-1-1

本文引用的文献

[1]
Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis.

Clin Gastroenterol Hepatol. 2021-5

[2]
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.

Hepatology. 2021-1

[3]
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

N Engl J Med. 2020-5-14

[4]
Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis.

Gut. 2021-2

[5]
Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis.

Hepatology. 2021-2

[6]
Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.

Hepatology. 2020-11

[7]
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.

Gastroenterology. 2020-1-30

[8]
Advances in molecular classification and precision oncology in hepatocellular carcinoma.

J Hepatol. 2020-2

[9]
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Cancer Discov. 2019-10-1

[10]
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Clin Gastroenterol Hepatol. 2020-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索